SuperworthIovance Biotherapeutics shares outstanding IOVA
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 450.2M
- On a year earlier
- +34.6%
- more shares
Iovance Biotherapeutics had 450.2M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 34.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2024 | 304.9M | +19% |
| FY2023 | 255.9M | +55% |
| FY2022 | 164.8M | +5% |
| FY2021 | 156.9M | +7% |
| FY2020 | 146.7M | +16% |
| FY2019 | 126.3M | +6% |
| FY2018 | 119.1M | +64% |
| FY2017 | 72.8M | +17% |
| FY2016 | 62.1M | +30% |
| FY2015 | 47.9M | +74% |
| FY2014 | 27.6M | +55% |
| FY2013 | 17.8M | +2008% |
| FY2012 | 846.5K | +7% |
| FY2011 | 793.9K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 450.2M | +35% | |
| Q1 FY26 | 418.5M | +30% | |
| Q2 FY25 | 334.5M | +17% | |
| Q1 FY25 | 322.9M | +21% | |
| Q4 FY24 | 304.9M | +19% | |
| Q3 FY24 | 303.3M | +23% | |
| Q2 FY24 | 284.8M | +27% | |
| Q1 FY24 | 266.2M | +25% | |
| Q4 FY23 | 255.9M | +55% | |
| Q3 FY23 | 245.8M | +56% | |
| Q2 FY23 | 224.5M | +43% | |
| Q1 FY23 | 213.7M | +36% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Iovance Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.